Skip to main content

Prospects for a safe COVID-19 vaccine.

Publication ,  Journal Article
Haynes, BF; Corey, L; Fernandes, P; Gilbert, PB; Hotez, PJ; Rao, S; Santos, MR; Schuitemaker, H; Watson, M; Arvin, A
Published in: Sci Transl Med
November 4, 2020

Rapid development of an efficacious vaccine against the viral pathogen severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the cause of the coronavirus disease 2019 (COVID-19) pandemic, is essential, but rigorous studies are required to determine the safety of candidate vaccines. Here, on behalf of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Working Group, we evaluate research on the potential risk of immune enhancement of disease by vaccines and viral infections, including coronavirus infections, together with emerging data about COVID-19 disease. Vaccine-associated enhanced disease has been rarely encountered with existing vaccines or viral infections. Although animal models of SARS-CoV-2 infection may elucidate mechanisms of immune protection, we need observations of enhanced disease in people receiving candidate COVID-19 vaccines to understand the risk of immune enhancement of disease. Neither principles of immunity nor preclinical studies provide a basis for prioritizing among the COVID-19 vaccine candidates with respect to safety at this time. Rigorous clinical trial design and postlicensure surveillance should provide a reliable strategy to identify adverse events, including the potential for enhanced severity of COVID-19 disease, after vaccination.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Sci Transl Med

DOI

EISSN

1946-6242

Publication Date

November 4, 2020

Volume

12

Issue

568

Location

United States

Related Subject Headings

  • Viral Vaccines
  • Vaccination
  • Pneumonia, Viral
  • Pandemics
  • Humans
  • Drug Development
  • Disease Models, Animal
  • Coronavirus Infections
  • Clinical Trials as Topic
  • COVID-19 Vaccines
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., … Arvin, A. (2020). Prospects for a safe COVID-19 vaccine. Sci Transl Med, 12(568). https://doi.org/10.1126/scitranslmed.abe0948
Haynes, Barton F., Lawrence Corey, Prabhavathi Fernandes, Peter B. Gilbert, Peter J. Hotez, Srinivas Rao, Michael R. Santos, Hanneke Schuitemaker, Michael Watson, and Ann Arvin. “Prospects for a safe COVID-19 vaccine.Sci Transl Med 12, no. 568 (November 4, 2020). https://doi.org/10.1126/scitranslmed.abe0948.
Haynes BF, Corey L, Fernandes P, Gilbert PB, Hotez PJ, Rao S, et al. Prospects for a safe COVID-19 vaccine. Sci Transl Med. 2020 Nov 4;12(568).
Haynes, Barton F., et al. “Prospects for a safe COVID-19 vaccine.Sci Transl Med, vol. 12, no. 568, Nov. 2020. Pubmed, doi:10.1126/scitranslmed.abe0948.
Haynes BF, Corey L, Fernandes P, Gilbert PB, Hotez PJ, Rao S, Santos MR, Schuitemaker H, Watson M, Arvin A. Prospects for a safe COVID-19 vaccine. Sci Transl Med. 2020 Nov 4;12(568).

Published In

Sci Transl Med

DOI

EISSN

1946-6242

Publication Date

November 4, 2020

Volume

12

Issue

568

Location

United States

Related Subject Headings

  • Viral Vaccines
  • Vaccination
  • Pneumonia, Viral
  • Pandemics
  • Humans
  • Drug Development
  • Disease Models, Animal
  • Coronavirus Infections
  • Clinical Trials as Topic
  • COVID-19 Vaccines